Enfermedades Autoinmunes, Inflamatorias e Infecciosas » Fases Iniciales de la Psicosis
Coordinador de Grupo
Rafael Segarra Echevarria
Doctor en Medicina
Profesor asociado Unidad Docente Facultad de Medicina y Enfermería de la UPV/EHU, Dpto. Neurociencias
OSI Eskerraldea Enkarterri Cruces
Miembros del Grupo
Luis Felipe Callado Hernando
Rebeca Diez Alarcia
José Ignacio Eguiluz Uruchurtu
Ane Miren Gabilondo Urkijo
Igor Horrillo Furundarena
José Javier Meana Martínez
Oiane Mentxaka Solozabal
Benito Morentin Campillo
Jorge Emilio Ortega Calvo
Maria Recio Barbero
Maria del Carmen Rey Chans
Guadalupe Rivero Calera
Margarita Sáenz Herrero
Leyre Urigüen Echevarria
Arantzazu Zabala Rabadan
Líneas de Investigación
Trastornos Psicóticos - Epidemiología Clínica y Neurocognición.
Trastornos psicóticos - Factores diagnósticos, pronósticos y terapéuticos.
Consumo de nicotina en trastornos psicóticos - la hipótesis de la automedicación.
Alteraciones cognitivas - en trastornos psicóticos y posibles vías de tratamiento.
Actividades del Grupo

Los trastornos psicóticos son enfermedades mentales de elevada gravedad y cronicidad que afectan aproximadamente al 2,5% de la población, produciendo importantes costes personales y asistenciales.

Los principales objetivos de este equipo son:

Identificar factores pronóstico relevantes que permitan orientar el diseño de intervenciones para mejorar el curso de la enfermedad.

Identificar marcadores endofenotípicos que ayuden a los clínicos a apoyar de forma más fiable un diagnóstico psicótico específico durante las fases tempranas.

Determinar la presencia de un posible factor biológico que explique la alta prevalencia de consumo de tabaco en esta población y orientar intervenciones sobre esta adicción.

Definir el perfil de afectación cognitiva y su evolución tanto en fases tempranas como en pacientes crónicos y valorar la eficacia de la rehabilitación cognitiva como una posible herramienta terapéutica.

Esperamos obtener resultados que además de ofrecer una mayor comprensión sobre los mecanismos de la enfermedad, permitan diseñar nuevas estrategias de intervención destinadas a incrementar la salud y calidad de vida de estos pacientes.

Publicaciones Científicas

Rivero G, Brocos-Mosquera I, Meana JJ, Callado LF. ADRA2A gene expression and epigenetic regulation in postmortem prefrontal cortex of subjects with schizophrenia. Basic Clin. Pharmacol. Toxicol. 2018; 123: 62 - 63. MEETING ABSTRACT.

Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sanchez E, Gutierrez-Rojas L, Meana JJ. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs. 2018; 32(5): 411 - 420. FI: 4,206(Q1). DOI: 10.1007/s40263-018-0519-3. REVIEW.

Cordero N, Muguruza C, Perez-Palomar B, Munarriz-Cuezva E, Meana JJ, Ortega JE. Behavioural evaluation of a translational animal model of schizophrenia. Basic Clin. Pharmacol. Toxicol.. 2018; 123: 59 - 59. MEETING ABSTRACT.

Brocos-Mosquera I, del Moral AN, Morentin B, Meana JJ, Callado LF, Erdozain AM. Characterisation of spinophilin immunoreactivity in postmortem human brain homogenates. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2018; 81: 236 - 242. FI: 4,185(Q1). DOI: 10.1016/j.pnpbp.2017.09.019.

Ibarra-Lecue I, Mollinedo-Gajate I, Meana JJ, Callado LF, Diez-Alarcia R, Uriguen L. Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway. Neuropsychopharmacology. 2018; 43(10): 2028 - 2035. FI: 6,544(Q1). DOI: 10.1038/s41386-018-0076-y.

Zabala A, Salgueiro M, Saez-Atxukarro O, Ballesteros J, Ruiz-Irastorza G, Segarra R. Cognitive Impairment in Patients With Neuropsychiatric and Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. J. Int. Neuropsychol. Soc. 2018; 24(6): 629 - 639. FI: 2,777(Q2). DOI: 10.1017/S1355617718000073.

Lopez-Cardona AP, Ibarra-Lecue I, Laguna-Barraza R, Perez-Cerezales S, Uriguen L, Agirregoitia N, et al. Effect of chronic THC administration in the reproductive organs of male mice, spermatozoa and in vitro fertilization. Biochem. Pharmacol. 2018; 157: 294 - 303. FI: 4,235(Q1). DOI: 10.1016/j.bcp.2018.07.045.

Callado LF, Ibarra-Lecue I, Luque-Fernandez V, Meana JJ, Diez-Alarcia R, Uriguen L. Effects of chronic antipsychotics administration on akt-dependent signalling pathways in rat brain cortex. Basic Clin. Pharmacol. Toxicol.. 2018; 123: 58 - 58. MEETING ABSTRACT.

Muneta-Arrate I, Horrillo I, Perez-Palomar B, Martinez-Alberdi L, Ortega JE, Meana JJ. Evaluation of long-term desipramine administration on alpha (2)-adrenoceptors regulating noradrenaline and serotonin release in rat frontal cortex. Basic Clin. Pharmacol. Toxicol. 2018; 123: 59 - 59. MEETING ABSTRACT.

Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Matsuoka I, et al. Functional coupling between adenosine A(1) receptors and G-proteins in rat and postmortem human brain membranes determined with conventional guanosine-5 '-O-(3-[S-35]thio)triphosphate ([S-35]GTP gamma S) binding or [S-35]GTP gamma S/immunoprecipitation assay. Purinergic Signal. 2018; 14(2): 177 - 190. FI: 3,190(Q2). DOI: 10.1007/s11302-018-9603-x.

Herrero MS. Gender violence and mental health: a gap between clinical assistance and research. Actas Esp Psiquiatr. 2018; 46(1): 31 - 32. FI: 0,878(Q4). LETTER.

Martin-Hernandez D, Caso JR, Meana JJ, Callado LF, Madrigal JLM, Garcia-Bueno B, et al. Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants. J. Neuroinflamm. 2018; 15: 251. FI: 5,193(Q1). DOI: 10.1186/s12974-018-1294-2.

Pallas M, Grinan-Ferre C, Abas S, Rodriguez-Arevalo S, Bagan A, Vasilopoulou F, et al. Novel imidazoline i2 receptor ligands for cognitive decline treatment. Basic Clin. Pharmacol. Toxicol. 2018; 123: 54 - 54. MEETING ABSTRACT.

Ordonez-Carrasco JL, Salgueiro M, Sayans-Jimenez P, Blanc-Molina A, Garcia-Leiva JM, Calandre EP, et al. Psychometric properties of the Spanish version of the 12-item Interpersonal Needs Questionnaire in fibromyalgia syndrome patients. An. Psicol. 2018; 34(2): 274 - 282. FI: 0,756(Q4). DOI: 10.6018/analesps.34.2.293101.

Perez-Palomar B, Mollinedo-Gajate I, Berrocoso E, Meana JJ, Ortega JE. Serotonin 5-HT3 receptor antagonism potentiates the antidepressant activity of citalopram. Neuropharmacology. 2018; 133: 491 - 502. FI: 4,249(Q1). DOI: 10.1016/j.neuropharm.2018.02.020.

Brocos-Mosquera I, Gabilondo AM, Meana JJ, Callado LF, Erdozain AM. Spinophilin expression in postmortem prefrontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Basic Clin. Pharmacol. Toxicol. 2018; 123: 59 - 59. MEETING ABSTRACT.

Ibarra-Lecue I, Pilar-Cuellar F, Muguruza C, Florensa-Zanuy E, Diaz A, Uriguen L, et al. The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochem. Pharmacol.. 2018; 157: 97 - 107. FI: 4,235(Q1). DOI: 10.1016/j.bcp.2018.07.009. REVIEW.DOI:10.1016/j.ejmech.2017.06.008.

Ibi D, Revenga MD, Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA, et al. Antipsychotic-induced Hdac2 transcription via NF-kappa B leads to synaptic and cognitive side effects. Nat Neurosci. 2017;20:1247. FI:17,839(Q1). DOI:10.1038/nn.4616.

Fernandez-Pastor B, Ortega JE, Grandoso L, Castro E, Ugedo L, Pazos A, et al. Chronic citalopram administration desensitizes prefrontal cortex but not somatodendritic a2-adrenoceptors in rat brain. Neuropharmacology. 2017;114:114-22. FI:5,012(Q1). DOI:10.1016/j.neuropharm.2016.11.025.

MacDowell KS, Munarriz-Cuezva E, Caso JR, Madrigal JL, Zabala A, Meana JJ, et al. Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia. Neuropharmacology. 2017;116:196-207. FI:5,012(Q1). DOI:10.1016/j.neuropharm.2016.12.025.

Flood A, Trujillo C, Sanchez-Sanz G, Kelly B, Muguruza C, Callado LF, et al. Thiophene/thiazole-benzene replacement on guanidine derivatives targeting alpha(2)-Adrenoceptors. Eur J Med Chem. 2017;138:38-50. FI:4,519(Q1). DOI:10.1016/j.ejmech.2017.06.008.

Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, Gonzáles-Pinto A, et al; PEPs GROUP. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. Int J Neuropsychopharmacol. 2016; 19:pyv121 . FI:4,712(Q1). DOI: 10.1093/ijnp/pyv121.

Diez-Alarcia R, Ibarra-Lecue I, Lopez-Cardona AP, Meana J, Gutierrez-Adan A, Callado LF, et al. Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex. Front Pharmacol. 2016;7:415 . FI:4,400(Q1). DOI: 10.3389/fphar.2016.00415.

Garcia-Bueno B, Gasso P, MacDowell KS, Callado LF, Mas S, Bernardo M, et al. Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. J Psychiatry Neurosci. 2016;41:46-55. FI:5,165(Q1). DOI: 10.1503/jpn.150195.

Horrillo I, Ortega JE, Diez-Alarcia R, Uriguen L, Meana JJ. Effect of subchronic corticosterone administration on alpha(2)-adrenoceptor functionality in rat brain: an in vivo and in vitro study. Psychopharmacology. 2016;233:3861-7. FI:3,308(Q2). DOI: 10.1007/s00213-016-4418-3.

Mas S, Gassó P, Lafuente A, Bioque M, Lobo A, Gonzàlez-Pinto A, et al; PEPs GROUP. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics J. 2016;16: 439-45. FI:3,815(Q1). DOI: 10.1038/tpj.2016.44.

McMullan M, Garcia-Bea A, Miranda-Azpiazu P, Callado LF, Rozas I. Substituted conformationally restricted guanidine derivatives: Probing the alpha(2)-adrenoceptors' binding pocket. Eur J MeChem. 2016;123:48-57. FI:4,519(Q1). DOI: 10.1016/j.ejmech.2016.07.011.

Mezquida G, Penadés R, Cabrera B, Savulich G, Lobo A, González-Pinto A, et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. Eur Psychiat. 2016;38: 61-8. FI:3,123(Q2). DOI: 10.1016/j.eurpsy.2016.04.011.

Moreno JL, Miranda-Azpiazu P, Garcia-Bea A, Younkin J, Cui M, Kozlenkov A, et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci Signal. 2016;9:ra5. FI:6,494(Q1). DOI: 10.1126/scisignal.aab0467.

Muguruza C, Meana JJ, Callado LF. Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Front Pharmacol. 2016;7:130. FI:4,400(Q1). DOI: 10.3389/fphar.2016.00130.

Pinacho R, Villalmanzo N, Meana JJ, Ferrer I, Berengueras A, Haro JM, et al. Altered CSNK1E, FABP4 and NEFH protein levels in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res. 2016;177:88-97. FI:3,986(Q1). DOI: 10.1016/j.schres.2016.04.050.

Rivero G, Martín-Guerrero I, de Prado E, Gabilondo AM, Callado LF, García-Sevilla JA, et al. Alpha2C-adrenoceptor Del322-325 polymorphism and risk of psychiatric disorders: significant association with opiate abuse and dependence. World J Biol Psychiatry. 2016;17:308-15. FI:3,658(Q2). DOI: 10.3109/15622975.2016.1142608.

Agirregoitia E, Ibarra-Lecue I, Totorikaguena L, Mendoza R, Exposito A, Matorras R, et al. Dynamics of expression and localization of the cannabinoid system in granulosa cells during oocyte nuclear maturation. Fertil Steril. 2015;104:753-760. FI:4,426(Q1). DOI:10.1016/j.fertnstert.2015.06.013.

Arteaga O, Revuelta M, Urigueen L, Alvarez A, Montalvo H, Hilario E. Pretreatment with Resveratrol Prevents Neuronal Injury and Cognitive Deficits Induced by Perinatal Hypoxia-Ischemia in Rats. PLoS One. 2015; 10:e014242. FI:3,057(Q1). DOI:10.1371/journal.pone.0142424.

Bustillo M, Querejeta I, Segarra R, Gonzalez-Pinto A, Alonso M, Mentxaka O, et al. Plasma levels of second generation antipsychotics as indicators of clinical response and severity of side-effects in first-episode psychosis patients. Eur Neuropsychopharm. 2015;25:513-514. FI:4,409(Q1). ABSTRACT

Bustillo M, Segarra R, Querejeta I, Gonzalez-Pinto A, Mentxaka O, Carton J, et al. Is therapeutic drug monitoring of olanzapine a useful clinical tool in first-episode psychosis patients?. Eur Neuropsychopharm. 2015;25:63-64. FI:4,409(Q1). ABSTRACT

Erdozain AM, Rubio M, Meana JJ, Fernandez-Ruiz, J, Callado LF. Altered CB1 receptor coupling to G-proteins in the post-mortem caudate nucleus and cerebellum of alcoholic subjects. J Psychopharmacol. 2015;29:1137-1145. FI:3,637(Q1). DOI:10.1177/0269881115599388.

Erdozain AM, Rubio M, Valdizan EM, Pazos A, Meana JJ, Fernández-Ruiz J, et al. The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects. Addict Biol. 2015;20:773-783. FI:4,547(Q1). DOI:10.1111/adb.12160.

Gilabert-Juan J, Saez AR, Lopez-Campos G, Sebastia-Ortega N, Gonzalez-Martinez R, Costa J, et al. Semaphorin and plexin gene expression is altered in the prefrontal cortex of schizophrenia patients with and without auditory hallucinations. Psychiatry Res. 2015;229:850-857. FI:2,466(Q2). DOI:10.1016/j.psychres.2015.07.074.

Gil-Pisa I, Mollinedo Gajate I, Marmolejo S, Meana JJ, Gonzalez-Maeso J. Functional activity of the serotonin 5HT2A/MGLU2 receptors heterocomplex in mouse brain. Basic Clin Pharmacol. 2015;117:44. FI:3,097(Q2). ABSTRACT

Kelly B, McMullan M, Muguruza C, Ortega JE, Meana JJ, Callado LF, et al. Alpha(2)-Adrenoceptor Antagonists: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of Pyridinoguanidine, Pyridino-2-aminoimidazoline and Their Derivatives. J Med Chem. 2015;58:963-977. FI:5,589(Q1). DOI:10.1021/jm501635e.

Mollinedo-Gajate I, Gonzalez-Maeso J, Meana J. Functional interaction between serotonin 2A and metabotropic glutamate 2 receptors in the regulation of dopamine release in mouse prefrontal cortex. Eur Neuropsychopharm. 2015;25:261-262. FI:4,409(Q1). ABSTRACT

Mollinedo-Gajate I, Gonzalez-Maeso J, Meana JJ. Involvement of serotonin 2A-metabotropic glutamate 2 receptor heterocomplex in catecholamine release in mouse prefrontal cortex. Eur Neuropsychopharm. 2015;25:33-34. FI:4,409(Q1). ABSTRACT

Munarriz-Cuezva E, Prades R, Urigueen L, Royo S, Giralt E, Tarrago T, et al. The prolyl oligopeptidase inhibitor IPR19 improves cognitive deficits in schizophrenia-like mouse models. Eur Neuropsychopharm. 2015;25:479. FI:4,409(Q1). ABSTRACT

Odagaki Y, Kinoshita M, Ota T, Meana JJ, Callado LF, Garcia-Sevilla JA. Adenosine A(1) receptors are selectively coupled to G alpha(i-3) in postmortem human brain cortex: Guanosine-5 `-O-(3-[S-35]thio)triphosphate ([S-35]GTP gamma S) binding/immunoprecipitation study. Eur J Pharmacol. 2015;764:592-598. FI:2,730(Q2). DOI:10.1016/j.ejphar.2015.07.049.

Pinacho R, Saia G, Meana JJ, Gill G, Ramos B. Transcription factor SP4 phosphorylation is altered in the postmortem cerebellum of bipolar disorder and schizophrenia subjects. Eur Neuropsychopharm. 2015;25:1650-1660. FI:4,409(Q1). DOI:10.1016/j.euroneuro.2015.05.006.

Prades R, Munarriza-Cuezva E, Urigueen L, Royo S, Giralt E, Meana J, et al. Selective prolyl oligopeptidase inhibition by IPR19 as a new pharmacological treatment of the cognitive impairment associated with schizophrenia. Eur Neuropsychopharm. 2015;25:479-480. FI:4,409(Q1). ABSTRACT

Rivero G, Gabilondo AM, Garcia-Sevilla JA, La Harpe R, Morentin B, Meana JJ. Up-regulated 14-3-3 beta and 14-3-3 zeta proteins in prefrontal cortex of subjects with schizophrenia: effect of psychotropic treatment. Schizophr Res. 2015;161:446-451. FI:4,453(Q1). DOI:10.1016/j.schres.2014.12.014.

Morentin B, Ballesteros J, Callado LF, Meana JJ. Recent cocaine use is a significant risk factor for sudden cardiovascular death in 15-49-year-old subjects: a forensic case-control study. Addiction. 2014;109:2071-8. FI: 4,738(Q1)

Muguruza C, Miranda-Azpiazu P, Díez-Alarcia R, Morentin B, González-Maeso J, Callado LF, et al. Evaluation of 5-HT2A and mGlu(2/3) receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment. Neuropharmacology. 2014;86:311-8. FI: 5,106(Q1)

Rivero G, Gabilondo AM, García-Sevilla JA, La Harpe R, Callado LF, Meana JJ. Increased alpha(2)- and beta(1)-adrenoceptor densities in postmortem brain of subjects with depression: Differential effect of antidepressant treatment. J Affect Disord. 2014;167:343-50. FI: 3,383(Q2)

García-Fuster MJ, Díez-Alarcia R, Ferrer-Alcón M, La Harpe R, Meana JJ, García-Sevilla JA. FADD adaptor and PEA-15/ERK1/2 partners in major depression and schizophrenia postmortem brains: basal contents and effects of psychotropic treatments. Neuroscience. 2014;277:541-51. FI: 3,357(Q2)

Gil-Pisa I, Cebrián C, Ortega JE, Meana JJ, Sulzer D. Cytokine pathway disruption in a mouse model of schizophrenia induced by Munc18-1a overexpression in the brain. J Neuroinflamm. 2014;11:128. FI: 5,408(Q1)

O'Donovan DH, Muguruza C, Callado LF, Rozas I. Guanidine-based alpha(2)-adrenoceptor ligands: Towards selective antagonist activity. Eur J Med Chem. 2014;82:242-54. FI: 3,447(Q1)

Erdozain AM, Morentin B, Bedford L, King E, Tooth D, Brewer C, et al. Alcohol-Related Brain Damage in Humans. PLoS One. 2014;9:e93586 . FI: 3,234(Q1)

Fernández-Fernández C, Callado LF, Girón R, Sánchez E, Erdozain AM, López-Moreno JA, et al. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Des Dev Ther. 2014;8:263-77. FI: 3,028(Q2)

Meana JJ, Callado LF, Morentin B. Do post-mortem brain studies provide useful information for Psychiatry?. Rev Psiquiatr Salud Ment. 2014;7:101-3. FI: 1,622(Q3)

Gabilondo AM. Evaluation experience in research projects. Basic Clin Pharmacol Toxicol. 2014;115:3-4. FI: 2,377(Q2)

Erdozain AM, Callado LF. Neurobiological alterations in alcohol addiction: a review. Adicciones. 2014;26:360-70. FI: 1,154(Q4)

Ballesteros J, Guillen V, Zabala A, Santos B, Rueda JR, Sola I. Clinical outcomes in schizophrenia treated with donepezil in combination with antipsychotics. Value Health 2013;16:542. FI: 2,191(Q1). ( Meeting Abstract)

Fernández-Pastor B, Ortega JE, Meana JJ. Involvement of serotonin 5-HT3 receptors in the modulation of noradrenergic transmission by serotonin reuptake inhibitors: a microdialysis study in rat brain. Psychopharmacology. 2013;229:331-44. FI: 4,061(Q1)

Ormaza M, Fernandez L, Lafuente S, Corso M, Schiller F, Xu B, et al. LaAu2 and CeAu2 surface intermetallic compounds grown by high-temperature deposition on Au(111). Phys Rev B. 2013;88: -0. FI: 3,767(Q1)

Meana JJ. Agonist signal trafficking at serotonin 5-ht2a receptor in human brain: implications for schizophrenia and antipsychotic treatment. Basic Clin Pharmacol Toxicol. 2013;113:6. FI: 2,124(Q3). ( Meeting Abstract)

Meana JJ, Fernandez-Pastor B, Ortega JE, Grandoso L, Castro E, Ugedo L, et al. Chronic citalopram administration desensitizes prefrontal cortex but not somatodendritic a2-adrenoceptors in rat brain. Basic Clin Pharmacol Toxicol. 2013;113:17. FI: 2,124(Q3). ( Meeting Abstract)

Meana JJ, Miranda-Azpiazu P, Muguruza C, Diez-Alarcia R, Callado LF, Gonzalez-Maeso J. Different pharmacological properties of ketanserin and altanserin on serotonin 5-ht2a receptors in postmortem human brain: interest for schizophrenia studies. Basic Clin Pharmacol Toxicol. 2013;113:17-8. FI: 2,124(Q3). ( Meeting Abstract).

Muguruza C, Moreno JL, Umali A, Callado LF, Meana JJ, González-Maeso J. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol. 2013;23:852-64. FI: 4,595(Q1)

Muguruza C, Lehtonen M, Aaltonen N, Morentin B, Meana JJ, Callado LF. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophr Res. 2013;148:145-50. FI: 4,590(Q1)

Pinacho R, Villalmanzo N, Roca M, Iniesta R, Monje A, Haro JM, et al. Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: A pilot study of relationship to negative symptoms. J Psychiatr Res. 2013;47:926-34. FI: 4,066(Q1)

Ortega JE,  Gonzalez-Lira V, Horrillo I, Herrera-Marschitz M, Callado LF, Meana JJ. Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain. Eur J Pharmacol. 2013;709:13-9. FI: 2,592(Q2)

Ramos-Miguel A, Meana JJ, García-Sevilla JA. Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: basal contents and effects of psychotropic medications. Int J Neuropsychopharmacol. 2013;16:683-9. FI: 5,641(Q1)

Ojeda N, Peña J, Bengoetxea E, García A, Sánchez P, Elizagárate E, et al. Evidence of the effectiveness of cognitive rehabilitation in psychosis and schizophrenia with the REHACOP programme Reply. Rev Neurol. 2013;56:400. FI: 1,179(Q4)

Rivero G, Gabilondo AM, García-Sevilla JA, Callado LF, La Harpe R, Morentin B, et al. Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment. Psychopharmacology. 2013;226:177-88. FI: 4,061(Q1)

Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, et al. Description of a Bivalent Cannabinoid Ligand with Hypophagic Properties. Arch Pharm. 2013;346:171-9. FI: 1,540(Q2)

Muguruza C, Rodríguez F, Rozas I, Meana JJ, Urigüen L, Callado LF. Antidepressant-like properties of three new alpha 2-adrenoceptor antagonists. Neuropharmacology. 2013;65:13-9. FI: 4,114(Q1)

Urigüen L, Gil-Pisa I, Munarriz-Cuezva E, Berrocoso E, Pascau J, Soto-Montenegro ML, et al. Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia. Transl Psychiatr. 2013;3:e221 FI: 0,000(Q0)

Alba-Delgado C, Llorca-Torralba M, Horrillo I, Ortega JE, Mico JA, Sánchez-Blázquez P, et al. Chronic Pain Leads to Concomitant Noradrenergic Impairment and Mood Disorders. Biol Psychiatry. 2013;73:54-62. FI: 9,247(Q1)

Tesis

Autor/a: Jon García Ormaza. Título: Suicidio y desempleo: Barakaldo 2003-2014. Director/a: Dr. José Ignacio Eguiluz Uruchurtu, Dr. Rafael Segarra Echevarria. UPV/EHU

Autor/a: Mariana Bustillo Iceta. Título: Utilidad de la monitorización terapéutica de antipsicóticos de segunda generación en la práctica clínica de los primeros episodios psicóticos. Director/a: Dr. Rafael Segarra Echebarría, Dra. Arantzazu Zabala Rabadán. UPV/EHU

Autor/a: Eva Munarriz Cuezva. Título: Caracterización de las proteínas del complejo SNARE en esquizofrenia y su tratamiento. Director/a: Dra. Leyre Urigüen Echeverría, Dr. José Javier Meana Martínez. UPV/EHU